Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Icahn School of Medicine at Mount Sinai
Summary
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Description
Psychostimulants are the first-line pharmacotherapy for Attention deficit-hyperactivity disorder (ADHD), and MPH accounts for approximately 50% of all stimulant usage. There has been an \~10-fold increase in MPH prescribing since 1990, with 18 million prescriptions dispensed in 2010, including 1.9 million new starts on MPH, making it the 5th most commonly prescribed medication to children ages 2 -11 and the single most frequently prescribed medication of any type in those aged 12-17 years. The annual exposure of pediatric patients to MPH is extremely high and MPH is among the most commonly pre…
Eligibility
- Age range
- 6–17 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: \- Youth ages 6-17 years with ADHD as a primary diagnosis Exclusion Criteria: * Participants that do not have ADHD as a primary diagnosis * Participants that do not want, require, or are not healthy enough for a single dose trial of MPH for ADHD per the clinical judgment of the treating and study clinicians * Participants that are smokers or, are pregnant
Interventions
- DrugMethylphenidate
study to determine dose
Locations (4)
- University of FloridaGainesville, Florida
- Icahn School of Medicine at Mount SinaiNew York, New York
- Cincinnati Children's Hospital Medical CenterCincinnati, Ohio
- Seattle Children's HospitalSeattle, Washington